Business Description
Pluri Inc
NAICS : 325414
SIC : 2836
ISIN : US72940R1023
Total Employee Number:
142Description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | -0.71 | |||||
Debt-to-Equity | -1.81 | |||||
Debt-to-EBITDA | -1.32 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -28.67 | |||||
Beneish M-Score | -0.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 53.8 | |||||
3-Year EBITDA Growth Rate | 29.2 | |||||
3-Year EPS without NRI Growth Rate | 31.4 | |||||
3-Year FCF Growth Rate | 30 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.33 | |||||
Quick Ratio | 0.33 | |||||
Cash Ratio | 0.29 | |||||
Days Sales Outstanding | 78.75 | |||||
Days Payable | 525.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.8 | |||||
Shareholder Yield % | -17.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43 | |||||
Operating Margin % | -2410.84 | |||||
Net Margin % | -2366.91 | |||||
EBITDA Margin % | -2367.56 | |||||
FCF Margin % | -2010.68 | |||||
OCF Margin % | -1887.27 | |||||
ROA % | -76.73 | |||||
ROIC % | -66.84 | |||||
3-Year ROIIC % | 58.54 | |||||
ROC (Joel Greenblatt) % | -302.73 | |||||
ROCE % | -408.6 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.53 | |||||
PS Ratio | 16.85 | |||||
EV-to-EBIT | -2.01 | |||||
EV-to-Forward-EBIT | 2.36 | |||||
EV-to-EBITDA | -2.05 | |||||
EV-to-Revenue | 48.62 | |||||
EV-to-Forward-Revenue | 0.21 | |||||
EV-to-FCF | -2.42 | |||||
Price-to-GF-Value | 0.32 | |||||
Earnings Yield (Greenblatt) % | -49.75 | |||||
FCF Yield % | -96.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pluri Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.927 | ||
| EPS (TTM) (€) | -2.503 | ||
| Beta | 0.1919 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 5.6 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 5.6 - 5.6 | ||
| Shares Outstanding (Mil) | 10.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pluri Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pluri Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-11-12 | In 134 days | ||
| Annual report for 2026 | 2026-09-17 | In 78 days | ||
| General meeting for 2026 | 2026-06-15 13:00 | 5.60 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-05-14 | 5.60 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 5.60 (+0.00%) | ||
| Alliance Global Partners Virtual Emerging AgBiotech/Bio-Solutions Showcase | 2025-11-20 09:00 | 5.60 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-11-12 | 5.60 (+0.00%) | ||
| Annual report for 2025 | 2025-09-17 | 5.60 (+0.00%) | ||
| A.G.P.’s Annual Healthcare Company Showcase | 2025-05-21 09:00 | 5.60 (+0.00%) | ||
| General meeting for 2025 | 2025-05-14 17:00 | 5.60 (+0.00%) |
Show
Entries
Pluri Inc Frequently Asked Questions
What is Pluri Inc(FRA:4DX)'s stock price today?
The current price of FRA:4DX is €5.60. The 52 week high of FRA:4DX is €5.60 and 52 week low is €5.60.
When is next earnings date of Pluri Inc(FRA:4DX)?
The next earnings date of Pluri Inc(FRA:4DX) is 2026-08-14 Est..
Does Pluri Inc(FRA:4DX) pay dividends? If so, how much?
Pluri Inc(FRA:4DX) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event | 2024-11-12 |
Articles on Pluri Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers